Emmaus Life Sciences (OTCMKTS:EMMA – Get Free Report) released its quarterly earnings data on Friday. The company reported ($0.05) earnings per share for the quarter, Zacks reports.
Emmaus Life Sciences Price Performance
Shares of OTCMKTS EMMA remained flat at $0.01 during midday trading on Friday. Emmaus Life Sciences has a 1-year low of $0.01 and a 1-year high of $0.02. The firm has a fifty day moving average of $0.01 and a 200 day moving average of $0.01. The stock has a market cap of $808,308.04, a PE ratio of -0.10 and a beta of 9.32.
Emmaus Life Sciences Company Profile
Emmaus Life Sciences, Inc is a publicly traded specialty pharmaceutical company focused on the development and commercialization of therapies for sickle cell disease and other serious hematological disorders. Its lead product, Endari® (L-glutamine oral powder), received U.S. Food and Drug Administration approval in 2017 for reducing the acute complications of sickle cell disease in patients aged five years and older. Through targeted research and development, Emmaus is also advancing additional pipeline candidates aimed at addressing oxidative stress and protein aggregation pathways that underlie various blood disorders.
Emmaus markets Endari in the United States and has entered into licensing agreements to distribute the therapy in regions including sub-Saharan Africa, the Middle East, North Africa and Latin America.
See Also
- Five stocks we like better than Emmaus Life Sciences
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
